Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Keigher, C.
Right arrow Articles by Dunne, F.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Treating to target in type 2 diabetes

Carol Keigher

Department of Medicine, University College Hospital (UCHG) and National University of Ireland Galway (NUIG)

Gloria Avalos

Department of Medicine, University College Hospital (UCHG) and National University of Ireland Galway (NUIG)

Fidelma Dunne

Department of Medicine, University College Hospital (UCHG) and National University of Ireland Galway (NUIG), Fidelma.dunne{at}nuigalway.ie

Patients with type 2 diabetes have a three-fold increased risk of developing vascular disease with death in 75% due to a vascular complication. Large prospective studies have demonstrated the benefits of treating patients with type 2 diabetes to strict targets regarding blood pressure (BP), lipids and glucose. Using both American Diabetes Association and Joint British Societies/Guidelines we assessed the effectiveness of this `treat-to-target' policy in diabetic patients attending secondary care. Of 321 patient notes analysed 54—87% were within target for total cholesterol, 80—84% for LDL cholesterol, 77% for HDL cholesterol, 51% for triglycerides, 44—61% for systolic BP, 62% for diastolic BP and 30—44% for HbA1C. In the secondary care setting we are performing well for lipids, less well for BP and poorly for HbA1C.

Key Words: type 2 diabetes • blood pressure • lipids • glycaemic control.

References

  • Burant CF (ed.) Medical management of Type 2 Diabetes. 5th ed. Alexandria, VA, American Diabetes Association 2004.
  • American Diabetes Association. Economic costs of Diabetes in the US. In 2002. Diabetes Care 2003;26:917-32.[Abstract/Free Full Text]
  • Davidson JA Treatment of the patient with diabetes: importance of maintaining target HbA1C levels. Cur Med Res Opin 2004;20:1919.[CrossRef]
  • Saydah SH, Fradkin J., Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42.[Abstract/Free Full Text]
  • UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with-macrovascular and microvascular complications for type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
  • Ethisham S., Barrett TG, Shaw NJ Type 2 diabetes in UK children an emerging problem. Diabet Med 2000;17:867-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rosenbloom AL, Joe JR, Young RS, Winter WE Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999;22:345-54.[Abstract/Free Full Text]
  • Herman WH, Teutsch SM, Geiss LS Closing the Gap: The problem of Diabetes Mellitus in the United States. Diabetes Care 1985;8:391-406.[Abstract]
  • Laakso M. Epidemiology of diabetic dyslipidaemia. Diabetes Review 1995;340822
  • Arauz-Pacheco C., Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002;25:134-47.[Free Full Text]
  • UK 2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703-13.[Abstract/Free Full Text]
  • Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36); prospective observational study. BMJ 2000;321:412-19.[Abstract/Free Full Text]
  • Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lindholm LH, Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE). Lancet 2002; 359:1004-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.[Abstract/Free Full Text]
  • Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial. Lancet 2003; 361:2005-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Standards of Medical Care. American Diabetes Association. Diabetes Care 2006;29:S4-S42.[Free Full Text]
  • Joint British Societies Guidance Version 2 on prevention of cardiovascular disease in Clinical Practice. Heart 2005;91:1-52.[Abstract/Free Full Text]
  • Dauolt B., Server PS, Poultor NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perivdopril as required versus atenolol adding beudro flumethiazid as required, in the Angl-Scandivarian Cardic Outcomes Trial -bloop pressure lowering arm (ASCOT-BPLA) a multicentre randomised controlled trail. Lancet 2005;366:895-906.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zauchetti A., Julius S., Kyeldsen S. et al.Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an anlysis of findings from the VALUE trail. J Hypertens 2006;24:2163-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Skyler JS, Weinstock RS, Raskin P. Use of inhaled insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects: A 6-month randomized comparative trial. Diabetes Care 2005;28:1630.[Abstract/Free Full Text]
  • Norris SL, Engelgau MM, Narayan KM Effectiveness of self-management training in type 2 diabetes; a systematic review of randomised controlled trials. Diabetes Care 2001;24:561-87.[Abstract/Free Full Text]
  • Norris SL, Lau J., Smith SJ, Schmid CH, Engelgau MM Self management education for adults with type 2 diabetes: a meta analysis of the effect on glycaemic control. Diabetes Care 2002;25:1159-71.[Abstract/Free Full Text]
  • 6. Gary TL, Genkinger JM, Guallar E., Peyrot M., Brancati FL Meta-analysis of randomized educational and behavioural interventions in type 2 diabetes. Diabetes Educ 2003;29:488-501.[Abstract/Free Full Text]
  • Skinner TC, Davies MJ, Heller S., Khunti K. The effects of a structured education programme on illness beliefs, quality of life and physical activity in individuals newly diagnosed with type 2 diabetes. Results from the DESMOND pilot group. Diabetic Medicine 2005.
  • Davies MJ, Heller S., Khunti K., Skinner TC The DESMOND programme: from pilot phase to randomised control trial in a study of structured group education for people newly diagnosed with type 2 diabetes mellitus. Diabetic Medicine 2005;64:369-77.

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 2, 83-85 (2007)
DOI: 10.1177/14746514070070020601
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Keigher, C.
Right arrow Articles by Dunne, F.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?